Amylyx to pull ALS drug from market, cut 70% of staff; Parkinson’s disease may be helped by GLP-1 drug, new study finds

Taking stock of the drug industry, from the lab to the medicine chest

April 4, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kayana Szymczak for STAT STAT+ | Amylyx to pull ALS drug from market, cut 70% of staff Though new prescriptions won't be allowed, Amylyx will offer Relyvrio to patients who are currently taking it, free of charge. By Allison DeAngelis Parkinson's disease may be helped by GLP-1 drug, new study finds The booming class of GLP-1 drugs that includes Ozempic and Wegovy are showing potential to help conditions involving the brain. By Elaine Chen Opinion: For national security, the U.S. must maintain its biotech dominance How America maintains and extends its current advantage in biotech innovation may well determine the country's future. By John F. Crowley

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser